MARKET

CHRS

CHRS

Coherus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.76
-0.32
-1.84%
After Hours: 16.76 0 0.00% 16:13 10/20 EDT
OPEN
17.24
PREV CLOSE
17.08
HIGH
17.30
LOW
16.51
VOLUME
971.30K
TURNOVER
--
52 WEEK HIGH
23.03
52 WEEK LOW
10.86
MARKET CAP
1.20B
P/E (TTM)
7.38
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Healthcare: XLV Survey For October
A dashboard with metrics in healthcare industries.Value and quality scores, and their evolution since last month.A list of cheap stocks.
Seekingalpha · 2d ago
5 Value Stocks To Watch In The Healthcare Sector
Benzinga · 10/05 13:44
Hedge Funds Are Selling Coherus Biosciences Inc (CHRS)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index
Insider Monkey · 09/28 22:23
Our View On Coherus BioSciences' (NASDAQ:CHRS) CEO Pay
Denny Lanfear has been the CEO of Coherus BioSciences, Inc. (NASDAQ:CHRS) since 2010, and this article will examine...
Simply Wall St. · 09/13 15:10
Coherus Neulasta biosimilar loses preferred status at Express Scripts
Coherus BioSciences ([[CHRS]] -2.6%) slips on below-average volume in apparent reaction to the exclusion of Udencya (pegfilgrastim-cbqv), a biosimilar to Amgen's ([[AMGN]] -0.8%) Neulasta, from Express Scripts' 2021 preferred formulary
Seekingalpha · 08/20 19:28
Coherus BioSciences (CHRS) Q2 Earnings and Revenues Top Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/07 00:10
Coherus BioSciences Reports Second Quarter 2020 Financial Results
– Second Quarter UDENYCA® Net Sales of $135.7 Million – – Net Income of $59.0 Million – – Non-GAAP Net Income of $68.3 Million –REDWOOD CITY, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), toda
GlobeNewswire · 08/06 20:02
Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors
REDWOOD CITY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Directors effective July 30, 2020.  “We are very pleased to welcome Kimber
GlobeNewswire · 08/03 20:48
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CHRS. Analyze the recent business situations of Coherus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CHRS stock price target is 30.22 with a high estimate of 35.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 279
Institutional Holdings: 98.60M
% Owned: 137.96%
Shares Outstanding: 71.47M
TypeInstitutionsShares
Increased
65
15.64M
New
92
603.98K
Decreased
55
4.02M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.98%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/President/Chief Executive Officer/Director
Dennis Lanfear
Chief Financial Officer
Jean-Frederic Viret
Chief Operating Officer
Vincent Anicetti
Chief Technology Officer
.. ..
Chief Scientific Officer
Vladimir Vexler
Other
Thomas Fitzpatrick
Lead Director/Independent Director
Mats Wahlstrom
Director
Christos Richards
Director
Kimberly Tzoumakas
Independent Director
James Healy
Independent Director
V. Bryan Lawlis
Independent Director
Samuel Nussbaum
Independent Director
Ali Satvat
Independent Director
Mary Szela
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CHRS
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Coherus Biosciences Inc stock information, including NASDAQ:CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.